We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Cantex Pharmaceuticals announced Chimerix, worldwide licensee of Cantex's DSTAT investigational product, has reported promising results of the first cohort of patients hospitalized with COVID-19-associated Acute Lung Injury (ALI), suggesting that ...
Cantex announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Cantex's lead product candidate, CX-01, for the treatment of patients over age 60 receiving induction therapy for newly diagnosed acute myeloid leukemia (A